Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.

AbbVie has struck five-year cancer research pacts with Johns Hopkins University School of Medicine and Northwestern University's Lurie Cancer Center.

After passing on an option to buy Acetylon in the summer, Celgene has come back with a deal for a slimmed-down version of the biotech.

AstraZeneca has penned a pact to develop bicyclic peptides with Bicycle Therapeutics.

Halozyme Therapeutics has suffered a disappointment as the first phase of a $1 billion-plus collaboration with AbbVie ended in failure.

Let’s be honest, 2016 was a mess of year, and one that many of us will be happy to see the back of. It saw the loss of a series of beloved actors, actresses…

Viralytics just reported impressive data for its virus-based cancer therapy that could bring commercial partners out of the woodwork.

Bristol-Myers has teamed with Enterome to discover microbiome-derived biomarkers, drug targets and bioactive molecules relevant to its immuno-oncology team.

Roche has put together a cancer immunotherapy research network and committed up to $100 million to support collaborations between the 21 academic centers.

Partnering